STOCK TITAN
  1. Home
  2. SEC Filings
  3. PCVX
  4. [Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte CEO and trusts sell 24,237 shares

Vaxcyte, Inc. director and CEO Grant Pickering reported open-market sales of 24,237 shares of Common Stock on June 26, 2026.

Filing Impact
(Very High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. director and CEO Grant Pickering reported open-market sales of 24,237 shares of Common Stock on June 26, 2026. The transactions included sales by trusts for the benefit of his son and daughter, as well as shares held directly. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026. After the direct sales, he held 468,020 shares directly.

Insider PICKERING GRANT
Role CHIEF EXECUTIVE OFFICER
Sold 24,237 shs ($1.34M)
Type Security Shares Price Value
Sale Common Stock 6,683 $54.275 $363K
Sale Common Stock 9,137 $55.265 $505K
Sale Common Stock 6,417 $56.121 $360K
Sale Common Stock 312 $54.345 $17K
Sale Common Stock 356 $55.226 $20K
Sale Common Stock 332 $55.993 $19K
Sale Common Stock 207 $54.222 $11K
Sale Common Stock 602 $55.297 $33K
Sale Common Stock 191 $56.266 $11K
Holdings After Transaction: Common Stock — 452,466 shares (Direct); Common Stock — 134,215 shares (Indirect, By Children's Trust)
Footnotes (12)
  1. F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
  2. F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.755 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.755 to $55.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. F4. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.815 to $56.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. F5. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. F6. Shares are held directly by a trust for the benefit of the Reporting Person's son.
  7. F7. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  8. F8. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.88 to $56.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  9. F9. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  10. F10. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
  11. F11. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  12. F12. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Total shares sold 24,237 shares Net open-market sales on June 26, 2026
Direct holdings after sale 468,020 shares Common Stock held directly after June 26, 2026 transactions
Largest reported sale block 9,137 shares Single open-market sale at $55.265 per share
Highest reported transaction price $56.266 per share Weighted-average price for a 191-share sale
Lowest reported transaction price $54.222 per share Weighted-average price for a 207-share sale
Net buy/sell direction Net sell of 24,237 shares Form 4 transaction summary for June 26, 2026
Rule 10b5-1 trading plan regulatory
"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported is a weighted-average price. The shares were sold at prices ranging from $53.755 to $54.75."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
open-market sale financial
"transaction_action: open-market sale; transaction_code_description: Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Children's Trust financial
"nature_of_ownership: By Children's Trust; Shares are held directly by a trust for the benefit of the Reporting Person's son."
indirect ownership financial
"direct_or_indirect: I; ownership_type: indirect; nature_of_ownership: By Children's Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Vaxcyte (PCVX) report for Grant Pickering?
Vaxcyte reported that CEO and director Grant Pickering was associated with open-market sales of 24,237 shares of Common Stock on June 26, 2026. The sales involved both directly held shares and shares held by trusts for the benefit of his children.

At what prices were the Vaxcyte (PCVX) shares sold in this Form 4?
The reported sales occurred at weighted-average prices around the mid-$50s per share. Individual weighted-average prices in the transactions ranged from $54.222 to $56.266, with footnotes noting underlying sale prices between about $53.755 and $56.60 per share.

How many Vaxcyte (PCVX) shares did Grant Pickering hold after the reported sales?
After the reported open-market sales of directly held shares, Grant Pickering held 468,020 shares of Vaxcyte Common Stock directly. Additional shares were held indirectly through trusts for the benefit of his son and daughter, as noted in the Form 4 footnotes.

Were Vaxcyte (PCVX) CEO Grant Pickering’s stock sales pre-planned?
Yes. A footnote states the reported sale was effected under a Rule 10b5-1 trading plan adopted on March 3, 2026. Such plans pre-schedule trades, indicating these transactions followed a predetermined program rather than ad hoc market timing decisions.

Did family trusts participate in the Vaxcyte (PCVX) insider transactions?
Yes. The Form 4 notes that some shares were held by a trust for the benefit of Grant Pickering’s son and a trust for the benefit of his daughter. These trusts conducted part of the reported open-market sales, classified as indirect ownership on the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Accepted by SEC EDGAR
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PICKERING GRANT
(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CHIEF EXECUTIVE OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/26/2026S(1)6,683D$54.275(2)468,020D
Common Stock06/26/2026S(1)9,137D$55.265(3)458,883D
Common Stock06/26/2026S(1)6,417D$56.121(4)452,466D
Common Stock06/26/2026S(1)312D$54.345(5)134,903IBy Children's Trust(6)
Common Stock06/26/2026S(1)356D$55.226(7)134,547IBy Children's Trust(6)
Common Stock06/26/2026S(1)332D$55.993(8)134,215IBy Children's Trust(6)
Common Stock06/26/2026S(1)207D$54.222(9)135,008IBy Children's Trust(10)
Common Stock06/26/2026S(1)602D$55.297(11)134,406IBy Children's Trust(10)
Common Stock06/26/2026S(1)191D$56.266(12)134,215IBy Children's Trust(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
2. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.755 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.755 to $55.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.815 to $56.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
5. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
6. Shares are held directly by a trust for the benefit of the Reporting Person's son.
7. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
8. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.88 to $56.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
9. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
10. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
11. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
12. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Remarks:
Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on PCVX

All PCVX news

Trending in the feed

LQDA
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Open the live feed